About

Opus Medical Therapies is developing a transseptal transcatheter mitral valve replacement (TMVR) device leveraging its proprietary anchoring platform. The Opus anchoring platform can be used to secure any intracardiac implant but the company is currently focused on addressing the challenging mitral regurgitation market. The Opus TMVR device treats primary and secondary mitral regurgitation while allowing normal cardiac motion.

The Opus Transcatheter Mitral Valve Replacement (TMVR) device is designed to treat MR using a transfemoral, transseptal delivery system. The Opus Valve is a self-expanding bioprosthetic valve tethered to an interventricular anchor that can accommodate various annulus sizes and anatomies. Independently adjustable tethers allows the Opus Valve to seal against the native mitral annulus with no paravalvular leakage (PVL) and a low stent profile reduces risk of left ventricular outflow tract (LVOT) obstruction.